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ABSTRACT 
 
Objective: To evaluate a modified extended Timed Up and Go (extended-TUG) assessment 
against a panel of validated clinical assessments, as an indicator of Parkinson’s disease (PD) 
severity and cognitive impairment. 
Methods: Eighty-seven participants with idiopathic PD were sequentially recruited from a 
Movement Disorders Clinic. An extended-TUG assessment was employed which required 
participants to stand from a seated position, walk in a straight line for 7 metres, turn 180 
degrees and then return to the start, in a seated position. The extended-TUG assessment 
duration was correlated to a panel of clinical assessments, including the Unified Parkinson’s 
Disease Rating Scale (MDS-UPDRS), Quality of Life (PDQ-39), Scales for Outcomes in 
Parkinson’s Disease (SCOPA-Cog), revised Addenbrooke’s Cognitive Index (ACE-R) and 
Barratt’s Impulsivity Scale 11 (BIS-11). 
Results: Extended-TUG time was significantly correlated to MDS-UPDRS III score and to 
SCOPA-Cog, ACE-R (p<0.001) and PDQ-39 scores (p<0.01). Generalized linear models 
determined the extended-TUG to be a sole variable in predicting ACE-R or SCOPA-Cog 
scores. Patients in the fastest extended-TUG tertile were predicted to perform 8.3 and 13.4 
points better in the SCOPA-Cog and ACE-R assessments, respectively, than the slowest 
group. Patients who exceeded the dementia cut-off scores with these instruments exhibited 
significantly longer extended-TUG times.    
Conclusions: Extended-TUG performance appears to be a useful indicator of cognition as 
well as motor function and quality of life in PD, and warrants further evaluation as a first line 
assessment tool to monitor disease severity and response to treatment. Poor extended-TUG 
performance may identify patients without overt cognitive impairment form whom cognitive 
assessment is needed.   
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INTRODUCTION 
 
Parkinson’s disease is recognised by an assortment of clinical signs, and may include a 
resting tremor, bradykinesia, rigidity, reduced postural reflexes, emotional disturbance, sleep 
disturbance, and cognitive decline. Although traditionally framed as a motor disorder, a 
plethora of non-motor symptoms has permitted the identification of a broad cognitive decline 
in some PD patients. Indeed, non-motor items in the Unified Parkinson’s Disease Rating 
Scale are thought to confer accuracy in the determination of quality of life than motor 
symptoms
1, 2
. Of these, cognitive impairment is most burdensome to individuals and their 
carers.  
 
Cluster analyses
3
, longitudinal and epidemiological work
4
 have illustrated complexity in the 
distribution, nature, and pattern of cognitive decline in PD. The heterogeneity of the 
cognitive deficits in PD patients significantly complicates the clinical diagnosis, but usually 
includes deficits in executive functions
5
, attention
6
, and working memory
7
. Moreover, the 
postural instability-gait dominant subtype of PD demonstrates a more accelerated cognitive 
decline than the tremor dominant subtypes
8, 9
 and in idiopathic PD patients, freezing and gait 
difficulties have been correlated to quality of life and cognitive impairment
9, 10
.   
 
Motor assessments routinely used in the clinic, such as a 10m Walk, and the Timed “Up and 
Go” (TUG)11, may potentially be indicators of both motor and cognitive aspects of the 
disease. A recent study found an increasing TUG time correlated with decreasing verbal 
fluency and quality of life, and could accurately predict a propensity for falling
12
. However, 
the traditional TUG assessment can show variability in correlating to aspects of PD, and is 
constrained by its inability to differentiate between control subjects, when using test duration 
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alone
13
. More recently, a modification to the traditional TUG, whereby total distance is 
increased from 6 to 14 metres, has enabled a more accurate gait assessment in PD
14
. Further, 
the extended-TUG was found to be a valid treatment outcome measure, irrespective of 
location (home or clinic) or practitioner discipline
15
. When coupled with instrumental 
analysis, subcomponents of the TUG are also more sensitive in identifying patient group 
differences, particularly in early PD
16
. It has previously been hypothesized that the improved 
sensitivity of this assessment may be due to the longer walking distance, potentially 
providing greater functional information of relevance to how patients manage with everyday 
tasks
17
. The extended-TUG assessment also correlates closely with patient quality of life
18
, a 
composite outcome measure derived from cognitive, motor and other aspects of the disease.  
 
In the present study, we characterized a heterogeneous Australian cohort of idiopathic PD 
(IPD) patients with the objective of determining readily accessible measures of disease status. 
We have employed a battery of demographic, motor, and cognitive assessments to elucidate 
key predictors of cognitive decline, in a diverse idiopathic PD cohort. Of these, an extended-
TUG assessment was shown to be an optimal marker of patient function, suggesting it has 
predictive potential across both motor and cognitive domains.  
 
METHODS 
 
Subjects 
 
Eighty-seven home-based patients with IPD were sequentially recruited from the Movement 
Disorders Clinics at the Western Australian Neuroscience Research Institute (Perth, 
Australia) between 2008-2015. All were ambulant and independent with activities of daily 
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living, none were known to have any other neurological disorder. Patients with dementia 
were not actively excluded. All patients were examined by a movement disorder neurologist 
prior to inclusion in the study for verification of the diagnosis in accordance with the UK 
Brain Bank criteria for IPD
19
. The study was approved by the Sir Charles Gairdner Hospital 
Human Research and Ethics Committee (Approval number 2006/073), and written informed 
consent was obtained from all participants, in accordance with the National Health and 
Medical Research Council guidelines.  
 
Clinical assessments 
 
The clinical evaluations included assessments of patient demographics and medications 
(Table 1), cognition, and other disease-related features. All PD medications were converted 
to levodopa equivalent daily doses (LEDD)
20
. Motor symptoms were evaluated in the ‘ON’ 
state using the MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III, and 
Hoehn and Yahr Scale
21
. The Abnormal Involuntary Movement Scale (AIMS) was used to 
grade the severity of involuntary movements in the sitting position, both at rest and during a 
backward counting task
22
.  
 
Each participant completed a battery of neuropsychological assessments with Clinical 
Psychologist. Global cognitive function was assessed using the ‘Scales for Outcomes in 
Parkinson's Disease-Cognition’ (SCOPA-Cog)23, and a revised ‘Addenbrooke’s Cognitive 
Examination’ (ACE-R)24. In addition, the Mini-Mental State Examination (MMSE), ‘Barrett 
Impulsivity Scale 11’ (BIS-11), a validated self-report for impulsivity25, and a revised 
‘Cambridge Behavioural Index’ (CBI-R) 26 with carer input were administered for each 
patient. For global quality of life (QoL), the summary index of the Parkinson's Disease 
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Questionnaire (PDQ-39)
27
 was used, with scores ranging from 0 (highest QoL) to 100 (lowest 
QoL). For establishing appropriate dementia cut-off scores, pre-determined cut-off scores for 
both the SCOPA-Cog (20
28
) and ACE-R (82.5
29
) assessments were utilised. s 
 
Extended Timed Up and Go assessment 
 
Participants completed a modified Timed Up and Go (TUG) assessment
11
, referred to 
hereafter as an extended-TUG assessment. Participants were assessed within a 3-hour 
morning window in a self-reported “ON” state as per their regular medication. were asked to 
sit correctly with their hips to the back of the seat, in a stable and standard chair equipped 
with armrests. The participants were allowed to use the armrests during the standing 
movement. Participants were instructed to stand up from their seated position, walk a 
distance of 7 meters at a comfortable pace, make a 180-degree turn, and then return to the 
start, in a seated position. The total duration taken to complete this modified and extended 
TUG was recorded. Participants were allowed gait assistive devices, but assistance by 
another person was not permitted. All assessments were conducted in the morning to 
standardize comparisons between the patients. Several studies have used and reported 
outcomes based on this lengthened walk distance using objective measures
13, 14, 30
.  
 
Statistical methods 
 
Data was analysed using IBM-SPSS (v. 23, IBM corporation). A significant nominal P-value 
of ≤0.05 was employed. Patients were grouped into tertiles according to extended-TUG times 
(Slow, Medium, Fast). Clinical assessment and patient variables were used to compare each 
of the tertile groups. One-way analysis of variance (ANOVA) tests were used to compare the 
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difference between participant groups, relative to demographic and clinical variables. Pearson 
correlation coefficients were calculated to determine the relationship between examined 
variables. The correlation criteria adopted were: r = .1 - .3 small, .3 - .5 moderate, .5 - .7 large 
and >.7 very large.   
 
Generalized linear models (GLM) were created to analyse the relationship between 
demographic and clinical variables, and cognitive function (determined by SCOPA-Cog and 
ACE-R assessments). The variables included in the GLMs were gender, disease duration, age 
of onset, Hoehn and Yahr stage, Schwab and England, and levodopa equivalent daily doses 
of medications (mg/day). Non-significant factors were removed singularly in order of least 
significance, until the final models were determined.  
 
RESULTS 
 
Cohort information and clinical data 
 
Mean demographic details and the results of clinical assessments are shown in Table 1. The 
IPD cohort enrolled in this study were predominantly male, broadly ranging in age, age of 
onset, and disease duration. The heterogeneous cohort displayed a relatively low mean Hoehn 
& Yahr [median (interquartile range)] 1 (1-2) score, and an average MDS-UPDRS III motor 
score of 12.8 (± 14.2). In addition, the PD cohort completed both ACE-R (M=78, SD=14.9) 
and SCOPA-Cog (M=23.8, SD=8.9) cognitive tools. 
 
Identification of correlates of cognition in the IPD cohort 
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In an initial screen, Pearson’s correlation analysis identified a number of markers associated 
with  cognitive status in the patient cohort. These results revealed a novel role for a modified, 
extended version of the TUG assessment, which showed a moderate correlation with 
performance on both the SCOPA-Cog (r= -.418, p <.001) and ACE-R (r= -.479, p<.001) 
assessments. Moreover, the correlation observed between the extended-TUG assessment and 
both cognitive tools was greater than the weaker correlation values observed with common 
demographic and quality of life assessments, such as age of onset, MDS-UPDRS I, and PDQ-
39 tools (Supplementary Table 1). 
 
Extended-TUG correlates with both cognitive and motor status 
 
To further investigate the extended-TUG assessment, demographic data, patient recorded 
outcomes, and clinical assessments were examined for potential relationships. Significant 
correlations (moderate and strong) were observed for the extended-TUG and a number of 
motor and cognitive variables (Table 2). Predictably, the extended-TUG correlated closely 
with assessments of overall disease severity, including the Hoehn & Yahr (r = 0.497, p 
<0.001), MDS-UPDRS III (r = 0.528, p<0.001), Schwab England (r = -.702, p <0.001) and 
additionally with the PDQ-39 (r= 0.558, p <0.001). Notably, moderate correlations were not 
limited to motor parameters, with an increase in extended-TUG time correlating to poorer 
performance in SCOPA-Cog (r = -.421, p <0.001), MMSE (r = -.546, p <0.001) and ACE-R 
(r = -.483, p <0.001). Weaker correlations were observed with the BIS-11 measure of 
impulsivity and CBI-R (Table 2). Conversely, the extended-TUG assessment did not 
correlate with levodopa equivalent dosage, age of onset or rest state AIMS score.  
 
Extended-TUG assessment significantly relates to cognitive and motor features of PD 
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To further illustrate the role of the extended-TUG assessment, subject performance was 
broken down into tertiles (Slow, Medium, Fast) on the basis of duration (i.e., time taken to 
complete the test). ANOVA or non-parametric analysis of tertiles revealed significant 
differences between the slowest tertile and fastest tertile in multiple clinical domains (Figure 
1). Patients falling into the slowest group performed significantly worse in SCOPA-Cog (p < 
.001) and ACE-R (p < .05) cognitive assessments than those in other groups. Moreover, the 
slowest group also had significantly lower QoL (PDQ-39; p < .001) and patient independence 
assessments (Schwab-England; p < .001). Similarly, clinical measures relating to disease 
severity, such as the MDS-UPDRS III and Hoehn and Yahr scale, related to the duration of 
the extended-TUG assessment. While demographic variables such as duration of disease and 
age at onset showed differences between groups, only the fastest group showed a 
significantly lower age of onset, when compared to other groups (p < .05). 
 
Extended-TUG assessment time predicts cognitive status in the IPD cohort 
 
A GLM was generated to discern predictors of patient cognition (SCOPA-Cog and ACE-R). 
Several potential demographic and clinical variables were inputted, and sequentially removed 
until all remaining variables showed statistical significance. In both models, disease duration, 
socio-economic indexation, gender, MDS-UPDRS domain III, DBS status, BIS-11, CBI-R, 
PDQ-39, smoking history, family history, and daily levodopa equivalence were found not to 
be significant predictors of SCOPA-Cog or ACE-R performance. The final models derived 
are reported in Table 3 and Table 4, and indicates that the extended-TUG assessment is the 
singular important predictor of cognitive performance. Specifically, the extended-TUG 
assessment was a determinant of total SCOPA score (maximum 60 points): patients in the 
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fastest tertile were predicted to score 8.3 points higher than those in the slowest tertile (p 
<.001; Table 3); likewise, patients in the fastest tertile were predicted to score 13.4 points 
higher in total ACE-R score than those in the slowest tertile (p <.001; Table 4). 
Classification of cognitive state using the extended-TUG assessment 
 
Following the identification of the extended-TUG assessment as a significant predictor of 
cognitive function, we tested whether the clinical state of cognitive impairment (i.e., 
cognitively impaired versus non cognitively impaired participants) could be identified from 
the time taken to complete the extended-TUG assessment. We divided the cohort into 
CI/non-CI groups using published dementia cut off scores of 19.5 and 82.5 for the SCOPA-
Cog and ACE-R assessment tools respectively. Using previously defined cognitive 
impairment cut-off scores there were 45 and 29 subjects classified as cognitively impaired, 
for ACE-R and SCOPA-Cog, respectively. Boxplots were generated to visualize performance 
in the extended-TUG assessment relative to the cognitive state of each group (Figure 2). 
When using both the SCOPA-Cog (p <.001) and ACE-R (p = .017) cognitive cut-off points, 
the CI group performed significantly worse than the non-CI groups.  
 
DISCUSSION 
 
A dichotomy of motor and non-motor symptomatology is well established in the diagnosis, 
assessment and treatment of PD. Recent work on the profile of cognitive impairment in PD 
has begun to alter this conceptual paradigm, however there remains a dependency on 
traditional non-motor assessments for the characterization of cognitive decline. In the current 
study, several commonplace assessments were related to disease parameters and the current 
gold standard motor examination (domain III of the MDS-UPDRS). Predictably, motor 
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examination scores were correlated with age of onset, quality of life and disease duration, 
however an extended TUG assessment emerged as the strongest correlate for all key 
parameters of PD, highlighting it as a candidate for further investigation. 
 
Previous studies have identified similar, albeit weaker relationship, between a clinical 
measure and both motor and cognitive patient outcomes. For example, Campos and 
colleagues (2015) recently demonstrated that the UPDRS III motor score could also predict 
cognitive impairment, with each additional point in the UPDRS III increasing the odds of 
dementia by 22%
31
. However, there is a lack of correlation between the UPDRS III motor 
score and quality of life
32
, which is a common indicator of disease severity. In the present 
study, when broken into tertiles on the basis of duration, the extended-TUG significantly 
differentiated between a range of clinical markers of PD severity, patient independence, and 
quality of life. Most striking was the slowest group, which performed significantly worse in 
all clinical measures, and was characterized by patients with an increased disease duration 
and an increased disease severity. Such a finding has not previously been reported when 
using an extended TUG assessment, however utilizing additional instrumental parameters has 
allowed for disease severity differentiation
13
.  
 
To investigate what role the extended-TUG assessment could have in predicting cognitive 
scores, a generalized linear model incorporating a large bank of potential variables, including 
MDS-UPDRS III was utilized. The results established the extended-TUG as the single best 
predictor of PD cognition in both SCOPA-Cog and ACE-R assessments. The results 
demonstrated that an extended-TUG time greater than 15.3 seconds (i.e., membership of the 
slowest group in our study), predicts cognitive scores of 19 in the SCOPA-Cog and 70 in the 
ACE-R. Importantly, both models predict patient cognitive function to be below previously 
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defined cut-off scores used to indicate dementia
28
. This observation is pertinent given the 
poor correlation of cognitive scores with numerous validated outcomes, including age of 
onset and disease duration in previous studies
33, 34
. Moreover, in the present study, the 
validated MDS-UPDRS III measure was not found to be a significant predictor of cognitive 
performance in each model.  
 
That the extended-TUG assessment, ostensibly a motor test, can predict cognitive status 
indicates the inherent complexity in PD pathophysiology, and the need to routinely assess 
non-motor symptoms. While the standard TUG has widely been documented as an effective 
first line motor examination, more recent studies have illustrated the applicability of this tool 
in determining aspects of patient cognition
35
. In PD pathophysiology, the dual syndrome 
hypothesis describes concurrent frontostriatal neurotransmitter depletion and sub-cortical 
atrophy
36
. The assertion that motor and cognitive symptoms are shared in PD, anchored by 
subcortical pathology, is further supported by the gait literature. For example, impairment of 
executive function, attention and verbal fluency have been reported to associate with slowed 
gait speed, falls risk, and impaired balance
8-10
. 
 
In light of the present findings, we propose the extended-TUG as a first-line holistic 
assessment of PD severity; integrating aspects of cognition, motor function and quality of 
life. There are logistical advantages of such a multipurpose preliminary assessment, most 
notably the short time required and lack of need for specialist interpretation. Moreover, an 
extended-TUG duration beyond 15 seconds could flag patients with presumptive cognitive 
impairment for further assessment. However, a patient’s extended-TUG assessment must be 
interpreted in an individual’s context, as reported confounders of walking speed include 
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medication, existing injuries, or other causes of gait disturbance (such as a previous 
cerebrovascular event)
37, 38
.  
 
LIMITATIONS  
 
To overcome possible selection bias, home-based PD patients were recruited sequentially 
from numerous clinics across the Perth metropolitan region. A single researcher was involved 
in the timing of each patient; a considerable limitation was the single duration measure of 
time, rather than timed segments (sit to stand, time at turn and so forth). A second limitation 
was the allowance of walking assistance tools, which were not excluded due to the increased 
risk of patient falls imposed by doing so. Statistical limitations should also be considered. 
Patient selection was made on the basis of independence and mobility in that those unable to 
walk unassisted were excluded, as demonstrated by a comparatively low mean cohort Hoehn 
and Yahr score. Patient medication was optimized, but LEDD, not specific medication type, 
was considered as a variable in GLMs. Use of a medication subclass, dopamine agonists, was 
recorded as a binary variable at the time of visit and incorporated as a variable in the GLM, 
but was non-significant. This is the first publication incorporating an extended TUG and 
multiple cognitive assessments, and as such, external validation in larger patient populations 
is required. Of those who completed the test, eTUG duration must be interpreted cautiously 
in the context of each individual. 
 
CONCLUSIONS 
 
This is the first study correlating an extended-TUG assessment with multiple validated 
cognitive tools. We have demonstrated that the extended-TUG has emerged as arguably the 
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most clinically useful predictor of disease status, by motor and non-motor scores. 
Furthermore, the simplicity of this assessment allows for an initial screening and presumptive 
classification prior to the completion of gold standard tools, such as the MDS-UPDRS. 
Therefore, if an extended-TUG is consolidated as a robust indicator of cognitive status in 
larger cohorts, its applications are both immediate and deserving of further development. In 
the absence of obvious causes, poor extended-TUG performance could demarcate patients for 
whom in-depth cognitive assessment is indicated but not self-evident. We propose the 
extended-TUG as an accessible monitoring tool for disease progression and treatment 
response in PD. 
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FIGURE LEGENDS 
 
Figure 1. Assessment of the effects of extended-TUG tertiles (Fast, Medium, Slow) on (A) 
SCOPA-Cog, (B) ACE-R, (C) PDQ-39, and (D) Schwab-England clinical tools. 
 
Figure 2. Boxplot representation of cognitive state relative to extended-TUG assessment 
time (A) Classification of cognitive impairment (dementia cutoff <19), as determined by the 
SCOPA-Cog assessment. (B) Classification of cognitive impairment (dementia cutoff <74.5), 
as determined by the ACE-R assessment. 
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Table 1. Baseline Clinical Characteristics of the IPD cohort (n=87) used in this study.  
Clinical Characteristic/Assessment Mean (SD) or n 
Gender (n) Male 54 
 Female 33 
Age (Years) 68.9 (31.8) 
Age of onset (Years) 53.3 (10.2) 
Disease duration (Years) 10.4 (6.8) 
Treatment Duration (Years) 8.4 (6.8) 
Daily LD equivalents (mg/day) 671 (389) 
Schwab-England (0-100) 81.6 (13.9) 
Hoehn Yahr (Stage 0-4) 1.6 (1.0) 
UPDRS Score I 7.6 (4.4) 
 
II 17.8 (9.7) 
 
III 12.8 (14.2) 
 
IV 4.4 (6.5) 
Extended-TUG (Seconds) 14.8 (5.6) 
 
LD: Levodopa; UPDRS: Unified Parkinson’s Disease Rating Scale 
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Table 2. Pearson Correlates of the extended-TUG assessment 
Disease Variables Pearson Correlation (r) Significance (p) 
Disease Duration Years .287 .008 
Age at Onset Years .201 .069 
Daily LD equivalent  .115 .305 
Hoehn & Yahr Scale 
 
.497 <.001 
Schwab England 
 
-.701 <.001 
UPDRS III .528 <.001 
Abnormal Involuntary 
Movement Scale 
Rest .028 .800 
Active .280 .010 
ACE-R 
 
-.483 <.001 
MMSE 
 
-.546 <.001 
SCOPA-Cog 
 
-.421 <.001 
CBI 
 
.371 .001 
BIS-11 
 
-.232 .036 
PDQ-39 
 
.558 <.001 
 
LD: Levodopa; UPDRS: Unified Parkinson’s Disease Rating Scale. ACE-R: Addenbrooke’s 
Cognitive Examination-Revised; MMSE: Mini-Mental State Examination; SCOPA-Cog: 
Scales for Outcomes in Parkinson's Disease-Cognition; CBI-R: Cambridge Behavioural 
Index- revised. 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Table 3. Final Model Parameter Estimates:  Predictors of SCOPA-Cog score. 
Variable  β coefficient Std. Error Significance 
(Intercept)  18.964 1.5467 .000 
Extended-TUG Fast 8.332 2.2075 .000 
 Medium 5.607 2.1873 .010 
 Slowest 0
a
 .  
(Scale)  66.981
b
 10.3975  
 
*Comparison category set to zero 
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Table 4. Final Model Parameter Estimates:  Predictors of ACE-R score. 
 
Variable  β coefficient Std. Error Significance 
(Intercept)  70.214 2.6345 .000 
Extended-TUG Fast 13.440 3.7967 .000 
 Medium 10.363 3.7967 .006 
 Slowest 0
a
 .  
(Scale)  194.337
b
 30.7273  
 
*Comparison category set to zero 
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Extended “Timed Up and Go” Assessment as a Clinical Indicator of Cognitive State in 
Parkinson’s Disease  
 
Tess Evans
1
, Alexa Jefferson
2
, Michelle Byrnes
2-3
, Sue Walters
2-3
, Soumya Ghosh
2-3
, Frank 
L. Mastaglia
2-4
, Brian Power
1
, Ryan S. Anderton
2, 3, 5 * 
 
Highlights 
 Time to complete the extended Timed Up and Go correlated closely with validated 
motor and non-motor assessments 
 extended-TUG duration was the sole significant predictor of cognition as assessed by 
SCOPA-Cog and ACE-R score in respective generalised linear models 
 Larger cohorts and extended-TUG subcomponent analysis, are needed to consolidate 
the Extended-TUG as a holistic indicator of disease status 
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